References
- Yakub-Agha I, de La Salamoniere P, Ribaud P, et al Allogeneic bone transplantation for therapy-related myelodysplastic syndrome and acute myelogenous leukemia: a report of 70 patients—report of the French Society of bone marrow transplantation. J Clin Oncol 2000;18:963–971.
- Beaumont M, Sanz M, Carli PM, et al Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21:2123–2137.
- Pulsoni A, Pagano L, Lo Coco F, et al Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100:1972–1976.
- Tsimberidou A-M, Kantargian H, Keating MJ, Estey E. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? Leuk Lymphoma 2006;47:2282–2288.
- Mistry AR, Felix CA, Whitmarsh RJ, et al DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005;352:1529–1538.
- Hasan SK, Mays AN, , Ottone T, et al Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008;112:3383–3890.
- Mays AN, Osheroff N, Xaio Y, et al Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood 2010;115:326–330.
- Yin CC, Glassman AB, Lin P, et al Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia. Am J Clin Pathol 2005;123:840–848.
- Sohal J, Phan VT, Chan PV, et al A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 2003;101:3188–3197.
- Ravandi F, Estey E, Jones D, et al Effective treatment of acute promyelocytic leukemia with all-trans retinoic acid, arsenic trioxide, and gentuzumab ozogamicin. J Clin Oncol 2009;27:504–510.
- Malhotra P, Varma N, Arora N, et al Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients. Leuk Lymphoma 2010;51:938–941.